Vontobel Holding Ltd. Acquires 173,457 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Vontobel Holding Ltd. lifted its holdings in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 788.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 195,457 shares of the company's stock after acquiring an additional 173,457 shares during the quarter. Vontobel Holding Ltd. owned 0.09% of Allogene Therapeutics worth $416,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. The Manufacturers Life Insurance Company grew its holdings in Allogene Therapeutics by 1.2% during the third quarter. The Manufacturers Life Insurance Company now owns 486,023 shares of the company's stock valued at $1,361,000 after purchasing an additional 5,642 shares during the period. Nordea Investment Management AB grew its position in Allogene Therapeutics by 2.1% during the fourth quarter. Nordea Investment Management AB now owns 460,641 shares of the company's stock worth $986,000 after buying an additional 9,635 shares in the last quarter. Private Advisor Group LLC purchased a new position in shares of Allogene Therapeutics during the third quarter worth about $34,000. EP Wealth Advisors LLC increased its holdings in shares of Allogene Therapeutics by 125.6% in the 3rd quarter. EP Wealth Advisors LLC now owns 24,475 shares of the company's stock worth $69,000 after buying an additional 13,625 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its stake in Allogene Therapeutics by 64.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 40,219 shares of the company's stock valued at $113,000 after acquiring an additional 15,690 shares during the last quarter. 83.63% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Allogene Therapeutics

In other news, insider Timothy L. Moore sold 14,746 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $1.71, for a total transaction of $25,215.66. Following the sale, the insider now owns 250,713 shares in the company, valued at $428,719.23. This represents a 5.55 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Zachary Roberts sold 27,199 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $1.78, for a total transaction of $48,414.22. Following the sale, the executive vice president now owns 488,054 shares in the company, valued at approximately $868,736.12. The trade was a 5.28 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 71,067 shares of company stock worth $131,959. 24.30% of the stock is owned by corporate insiders.

Allogene Therapeutics Stock Down 4.0 %

Shares of NASDAQ:ALLO traded down $0.09 on Friday, hitting $2.17. 4,880,095 shares of the company traded hands, compared to its average volume of 7,002,393. Allogene Therapeutics, Inc. has a 52 week low of $1.32 and a 52 week high of $5.78. The stock has a 50 day simple moving average of $1.96 and a 200-day simple moving average of $2.37. The company has a market cap of $454.98 million, a PE ratio of -1.39 and a beta of 0.83.

Wall Street Analyst Weigh In

ALLO has been the subject of several research reports. HC Wainwright reaffirmed a "buy" rating and issued a $9.00 target price on shares of Allogene Therapeutics in a research note on Friday, November 8th. William Blair reissued an "outperform" rating on shares of Allogene Therapeutics in a research note on Thursday, November 14th. Finally, Piper Sandler decreased their target price on Allogene Therapeutics from $11.00 to $9.00 and set an "overweight" rating for the company in a report on Thursday, November 14th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $9.73.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).